Author + information
- Wenjie Tian,
- Rebecca Torguson,
- Marco De Magalhaes Pereira,
- Thibault Lhermusier,
- Hideaki Ota,
- Nevin Baker,
- Sarkis Kiramijyan,
- Eddie Koifman,
- Smita Negi and
- Ron Waksman
Little information is available regarding the comparison between the first- and second-generation drug-eluting stents (DES) following rotational atherecotmy (ROTA) for patients with heavily calcified coronary lesions (HCCL).
Ninety-nine patients with HCCL who underwent RA prior to first-generation DES (n=40, 53 lesions) or second-generation DES (n=59, 63 lesions) implantation were retrospectively analyzed. The primary endpoint was the rate of major adverse cardiac events (MACE).
Baseline clinical and procedural characteristics were similar between the two groups, except for more complex type C lesions (81.0% vs. 58.8%, p=0.01) and more proportion of post dilation (52.4% vs. 23.1%, p=0.001) in the second-generation DES group. The procedure success rate was similar in the two groups (95% vs. 100%, p=0.161). Compared with first-generation DES group, there were no differences regarding the occurrence of MACE (11.9% vs. 12.8%, p=1.000), TLR (3.6% vs. 2.7%, p=1.000) and all-cause death (8.5% vs. 10.3%, p=1.000) in the second-generation DES group at 1-year follow-up. No stent thrombosis was found in all patients.
The first- and second-generation DES following ROTA resulted in comparable outcomes in patients with HCCL at 1 year follow-up.
|Variable||1-st generation DES (n=40, 53 lesions)||2-nd generation DES (n=59, 63 lesions)||p- value|
|In-hospital MACE (%)||5.0||0||0.161|
|6 month follow-up (%)|
|All cause death||5.0||5.1||1.000|
|1 year follow-up (%)|
|All cause death||10.3||8.5||1.000|
MACE: Major adverse cardiac events; MI: Myocardial infarction; TLR: Target lesion revascularization